Vertex (NASDAQ: VRTX) director sells 266 shares under 10b5-1 plan

Rhea-AI Filing Summary

Vertex Pharmaceuticals director Sangeeta N. Bhatia reported an open-market sale of 266 shares of common stock at $500 per share. After this transaction, she directly owns 4,299 shares. The sale was made under a company-approved Rule 10b5-1 trading plan entered into on 05/27/2025.

Insider Trade Summary

Net Seller: 266 shares ($133,000)

Net Sell 1 txn

Insider Bhatia Sangeeta N.

Role Director

Sold 266 shs ($133K)

Type	Security	Shares	Price	Value
Sale	Common Stock	266	$500.00	$133K

Holdings After Transaction: Common Stock — 4,299 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bhatia Sangeeta N.

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		S(1)		266	D	$500	4,299	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/27/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did VERTEX PHARMACEUTICALS (VRTX) report for Sangeeta N. Bhatia?

Vertex reported that director Sangeeta N. Bhatia executed an open-market sale of 266 shares of common stock. The transaction was reported on Form 4 and reflects a routine insider trade disclosed to regulators.

At what price were the VRTX shares sold in Sangeeta N. Bhatia’s Form 4 filing?

The filing shows that 266 shares of Vertex common stock were sold at $500 per share. This per-share price comes directly from the reported transaction details in the Form 4 insider trading disclosure.

How many VERTEX PHARMACEUTICALS (VRTX) shares does Sangeeta N. Bhatia own after the sale?

After the reported transaction, Sangeeta N. Bhatia directly owns 4,299 shares of Vertex common stock. This post-transaction ownership figure is provided in the Form 4 and reflects her remaining direct holdings.

Was the VRTX insider sale by Sangeeta N. Bhatia under a Rule 10b5-1 plan?

Yes. A footnote explains the sale was made under a company-approved Rule 10b5-1 trading plan. The plan was entered into on 05/27/2025, indicating the transaction followed a pre-established trading schedule.

What is the nature of ownership reported for Sangeeta N. Bhatia’s VRTX shares?

The Form 4 classifies her holdings as direct ownership, indicated by the code “D”. This means the reported 4,299 shares following the transaction are held directly in her name rather than through an indirect entity.